PMID- 12135861
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20091111
IS  - 0007-4551 (Print)
IS  - 0007-4551 (Linking)
VI  - 89
IP  - 6
DP  - 2002 Jun
TI  - [Radio-chemotherapy combinations in non operable localized non small cell lung 
      carcinoma: updates and perspectives].
PG  - 599-611
AB  - Optimal treatment of non operable localized non small cell lung carcinoma (NSCLC) 
      continues to evolve. Increasing overall survival must evolute through improving 
      local tumoral control and eradication of probable occult metastasis. 
      Historically, median survival varies between 7 and 10 months with a standard 
      conventional fractionated radiotherapy (RT). Induction chemotherapy (CT) followed 
      by RT has demonstrated its superiority over RT alone, modality which is widely 
      utilised. Other studies revealed best results with decreasing metastatic 
      relapses. Three independent meta-analysis confirmed benefit obtained with 
      cisplatin based CT followed by RT that allowed to consider this association as a 
      gold standard. Other authors demonstrated an improvement of local control and 
      survival with concomitant RT-CT or hyperfractionated accelerated RT. Results of 
      all of these new therapeutic modalities still poor. Implication of new CT drugs 
      has conducted for an emergence of new studies finding to demonstrate more 
      encouraging results. Randomized trials are conducted in this way.
FAU - Hasbini, Ali
AU  - Hasbini A
AD  - Service de radiotherapie-oncologie, Centre hospitalier, avenue Leon-Blum, 60021 
      Beauvais Cedex, France.
FAU - Ozanne, Fabienne
AU  - Ozanne F
FAU - Ammarguellat, Hanifa
AU  - Ammarguellat H
FAU - Crequit, Jacky
AU  - Crequit J
FAU - Dolige, Thierry
AU  - Dolige T
FAU - Bouchaert, Eric
AU  - Bouchaert E
FAU - Dutel, Jean-Luc
AU  - Dutel JL
FAU - Durdux, Catherine
AU  - Durdux C
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les associations de radio-chimiotherapie dans les carcinomes bronchiques non a 
      petites cellules localises inoperables: actualites et perspectives.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Radiation-Sensitizing Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/*radiotherapy
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Combined Modality Therapy/methods
MH  - Forecasting
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/*radiotherapy
MH  - Radiation-Sensitizing Agents/therapeutic use
RF  - 103
EDAT- 2002/07/24 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/07/24 10:00
PHST- 2002/07/24 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/07/24 10:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2002 Jun;89(6):599-611.